Physician profile
Mark W Chang
NPI 1174632475
$5,833.51
in general payments reported to CMS, 2019-2025
25 companies · $737 in 2025
The $737 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $2,719 · 2021: $357 · 2022: $258 · 2023: $478 · 2024: $395 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $2,527.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $833.04 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $578.88 | 2019-2025 | Lifevest |
| Abbott Laboratories | $333.16 | 2019-2025 | Xience Skypoint, Assurity, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $241.07 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $235.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $231.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $209.25 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.88 | 2019-2022 | |
| Atricure, INC. | $97.79 | 2023-2024 | |
| Edwards Lifesciences Corporation | $56.67 | 2023 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $50.22 | 2023-2025 | Eluvia |
| Heartflow, INC. | $49.98 | 2022 | |
| Cardiovascular Systems INC. | $39.90 | 2019-2022 | |
| Astellas Pharma US INC | $39.11 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $34.63 | 2025 | Optowire |
| Lemaitre Vascular, INC. | $19.74 | 2019 | |
| Medtronic, INC. | $18.78 | 2025 | Selectsecure |
| Smith+Nephew, INC. | $18.23 | 2019 | |
| Scpharmaceuticals INC. | $17.83 | 2025 | |
| Angiodynamics, INC. | $15.71 | 2022 | |
| Chiesi USA, INC. | $15.34 | 2019 | |
| Merck Sharp & Dohme LLC | $14.54 | 2024 | Verquvo |
| Amgen INC. | $13.62 | 2024 | Repatha |
| Gilead Sciences, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.